On April 30, 2026, the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee reviewed a new treatment for advanced prostate cancer. The therapy combines capivasertib (Truqap) with abiraterone (Zytiga) for patients whose cancer has a PTEN gene loss. The decision is based on results from a large Phase 3 study called CAPItello-281. The trial […]
A study found a metabolic “off-switch” involved in early pancreatic cancer development. The research centers on mutations in the KRAS gene. Scientists discovered that reduced activity of two enzymes, G6PD and ME1, lowers production of NADPH, a key molecule that protects cells. This causes a buildup of reactive oxygen species, leading to cell damage and
Metabolic “Off-Switch” Discovery Offers New Path to Prevent Pancreatic Cancer Read More »
A new study has identified the protein SLC5A11 as the key reason the diabetes drug metformin can also work as a cancer treatment. Researchers used a genome-wide CRISPR screen and found that metformin must bind to SLC5A11 to trigger its anti-cancer effects. Without this protein, the drug loses its ability to work against tumors. The
SLC5A11 Identified as Key Target Behind Metformin’s Cancer-Fighting Effects Read More »
A new study reveals why pancreatic cancer is so resistant to treatment and points to a promising way to overcome it. Researchers found that a specific group of immune cells, called tumor-associated macrophages, help tumors build an “immunosuppressive fortress” that protects them from chemotherapy and immunotherapy. The study identified a key pathway involving a lipid
Early trial results from the AURORAS-1 and JYP0015M101 studies show that ERAS-0015, a new pan-RAS “molecular glue,” may be highly effective in treating solid tumors with KRAS G12X mutations, including lung and pancreatic cancers. In patients with non-small cell lung cancer, the drug achieved response rates of 62% in those receiving second-line or later treatment,
ERAS-0015 Shows Strong Early Responses in RAS-Mutant Lung and Pancreatic Cancers Read More »
The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to TERN-701, a new targeted drug for patients with Philadelphia chromosome–positive chronic myeloid leukemia who have already failed at least two prior treatments and do not carry the T315I mutation. Results from the Phase 1/2 CARDINAL trial, presented at the ASH Annual Meeting, showed
FDA Grants Breakthrough Status to TERN-701 for Hard-to-Treat CML Read More »
A study suggests that vitamin D may improve chemotherapy outcomes in women with breast cancer. Researchers gave 80 women over age 45 either 2,000 IU of vitamin D daily or a placebo during treatment. After six months, 43% of women taking vitamin D had no detectable cancer, compared to 24% in the placebo group. Most
Low-Dose Vitamin D Shows Promise in Boosting Breast Cancer Chemotherapy Outcomes Read More »
Researchers report that pancreatic cancer is not a disorganized mass, but a highly structured system of cooperating cells. In pancreatic ductal adenocarcinoma (PDAC), tumor growth depends on two distinct cell types working together. One group produces growth signals, while the other acts like stem cells that receive those signals and drive tumor expansion. The study
The U.S. Food and Drug Administration has accepted and granted Priority Review for zanidatamab (Ziihera) combined with chemotherapy, with or without tislelizumab, as a first-line treatment for HER2-positive advanced gastroesophageal cancer. A final decision is expected by August 25, 2026. The application is based on results from the HERIZON-GEA-01 trial, where the zanidatamab combination showed
The ACCESS trial shows that stem cell transplants no longer require a perfect donor match. Using post-transplant cyclophosphamide (PTCy), patients with mismatched unrelated donors achieved a 74.2% two-year survival rate without higher risks of chronic graft-versus-host disease or relapse. Even 7/8, 6/8, or 5/8 matches can now be effective. This approach has greatly expanded access